{Reference Type}: Journal Article
{Title}: Genomic profiling of a multi-lineage and multi-passage patient-derived xenograft biobank reflects heterogeneity of ovarian cancer.
{Author}: Qin T;Hu Z;Zhang L;Lu F;Xiao R;Liu Y;Fan J;Guo E;Yang B;Fu Y;Zhuang X;Kang X;Wu Z;Fang Z;Cui Y;Hu X;Yin J;Yan M;Li F;Song K;Chen G;Sun C;
{Journal}: Cell Rep Med
{Volume}: 5
{Issue}: 7
{Year}: 2024 Jul 16
{Factor}: 16.988
{DOI}: 10.1016/j.xcrm.2024.101631
{Abstract}: Ovarian cancer (OC) manifests as a complex disease characterized by inter- and intra-patient heterogeneity. Despite enhanced biological and genetic insights, OC remains a recalcitrant malignancy with minimal survival improvement. Based on multi-site sampling and a multi-lineage patient-derived xenograft (PDX) establishment strategy, we present herein the establishment of a comprehensive PDX biobank from histologically and molecularly heterogeneous OC patients. Comprehensive profiling of matched PDX and patient samples demonstrates that PDXs closely recapitulate parental tumors. By leveraging multi-lineage models, we reveal that the previously reported genomic disparities of PDX could be mainly attributed to intra-patient spatial heterogeneity instead of substantial model-independent genomic evolution. Moreover, DNA damage response pathway inhibitor (DDRi) screening uncovers heterogeneous responses across models. Prolonged iterative drug exposure recapitulates acquired drug resistance in initially sensitive models. Meanwhile, interrogation of induced drug-resistant (IDR) models reveals that suppressed interferon (IFN) response and activated Wnt/β-catenin signaling contribute to acquired DDRi drug resistance.